要想早日結(jié)束新冠疫情，就要解決疫苗分配不均的難題。世界衛(wèi)生組織先后在南非和韓國創(chuàng)建了技術(shù)中心，致力于再造莫德納新冠疫苗，并通過技術(shù)共享提高低收入國家的疫苗接種率。

The World Health Organization is creating a global training center to help poorer countries make vaccines, antibodies and cancer treatments using the messenger RNA technology that has successfully been used to make COVID-19 vaccines.

世界衛(wèi)生組織正在創(chuàng)建一個(gè)全球培訓(xùn)中心，幫助低收入國家使用mRNA技術(shù)研制疫苗、抗體和抗癌藥物，該技術(shù)已成功用于制造新冠肺炎疫苗。

At a press briefing in Geneva on Wednesday, WHO Director-General Tedros Adhanom Ghebreyesus said the new hub will be in South Korea and will share mRNA technology being developed by WHO and partners in South Africa, where scientists are working to recreate the COVID-19 vaccine made by Moderna Inc. That effort is taking place without Moderna’s help.

2月23日在日內(nèi)瓦舉行的新聞發(fā)布會(huì)上，世衛(wèi)組織總干事譚德塞表示，新的中心將設(shè)在韓國，并將分享世衛(wèi)組織和南非合作伙伴正在開發(fā)的mRNA技術(shù)。譚德塞表示，南非科學(xué)家正在努力重現(xiàn)莫德納制造的新冠疫苗。這項(xiàng)工作是在沒有莫德納公司幫助的情況下進(jìn)行的。

"Vaccines have helped to change the course of the COVID-19 pandemic but this scientific triumph has been undermined by vast inequities in access to these life-saving tools,” Tedros said.

譚德塞指出：“疫苗幫助改變了新冠疫情的進(jìn)程，但這一科學(xué)勝利被獲取這些救生手段方面存在的巨大不平等所破壞?！?/p>

It's the first time that WHO has supported such unorthodox efforts to reverse-engineer a commercially-sold vaccine, making an end run around the pharmaceutical industry, which has largely prioritized supplying rich countries over poor in both sales and manufacturing.

這是世界衛(wèi)生組織第一次支持這種對商業(yè)銷售的疫苗進(jìn)行逆向工程的非正規(guī)做法，從而在疫苗供應(yīng)上繞過制藥業(yè)。制藥業(yè)在銷售和制造方面大多優(yōu)先向富裕國家而不是低收入國家供應(yīng)。

Both Moderna and Pfizer-BioNTech, makers of the two authorized mRNA COVID-19 vaccines, have declined to share their vaccine recipe or technological know-how with WHO and its partners.

兩款獲得認(rèn)證的mRNA新冠疫苗的生產(chǎn)商莫德納和輝瑞都拒絕和世界衛(wèi)生組織及其合作伙伴分享自己的疫苗配方或技術(shù)秘密。

WHO said the shared technology would hopefully result not only in coronavirus vaccines, but would also be useful in making antibodies, insulin and treatments for diseases including malaria and cancer.

世衛(wèi)組織表示，這項(xiàng)共享技術(shù)不僅有望生產(chǎn)出新冠疫苗，還可能用于制造抗體、胰島素以及治療瘧疾和癌癥等疾病的藥物。

WHO’s chief scientist Dr. Soumya Swaminathan estimated that the attempt to recreate Moderna’s vaccine would probably not yield any usable shots until late next year or even 2024, but said that timeline could be shortened considerably if the manufacturer agreed to help.

世衛(wèi)組織首席科學(xué)家索米婭·斯瓦米納坦博士估計(jì)，再造莫德納疫苗的嘗試很可能要到明年年底甚至2024年才能產(chǎn)出任何可用的疫苗。但她表示，如果制造商同意提供幫助，這一時(shí)間可能會(huì)大大縮短。

The global disparity in access to COVID-19 vaccines is enormous. Africa currently produces just 1% of the world’s COVID-19 vaccines and only about 11% of its population is immunized. In contrast, a European nation like Portugal has had 84% of its population fully vaccinated, and over 59% of its people have also had a booster shot.

在獲得新冠疫苗方面，全球差異巨大。目前，非洲僅生產(chǎn)了全球1%的新冠疫苗，只有約11%的人口接種了疫苗。相比之下，像葡萄牙這樣的歐洲國家有84%的人口已完成了疫苗接種，超過59%的人還打了加強(qiáng)針。

Last week, WHO said six African countries — Egypt, Kenya, Nigeria, Senegal, South Africa and Tunisia — would receive the knowledge and technological know-how to make mRNA COVID-19 vaccines. Tedros said Wednesday that five more countries would now receive support from the South Africa hub: Bangladesh, Indonesia, Pakistan, Serbia and Vietnam.

上周，世衛(wèi)組織表示，埃及、肯尼亞、尼日利亞、塞內(nèi)加爾、南非和突尼斯這6個(gè)非洲國家將獲得制造mRNA新冠疫苗的知識(shí)和技術(shù)訣竅。譚德塞23日表示，現(xiàn)在又有5個(gè)國家將從南非中心獲得支持：孟加拉國、印度尼西亞、巴基斯坦、塞爾維亞和越南。

Earlier this year, the Cape Town company attempting to replicate Moderna Inc.’s COVID-19 shot said it had successfully made a candidate vaccine that will soon start laboratory testing.

今年早些時(shí)候，試圖“復(fù)制”莫德納新冠疫苗的開普敦公司表示，他們已經(jīng)成功研制出一款候選疫苗，很快將開始進(jìn)行實(shí)驗(yàn)室測試。

Scientists attempting to make Moderna’s vaccine say there is more information about that shot in the public domain and it’s believed to be slightly easier to manufacture than the one made by Pfizer-BioNTech.

試圖再造莫德納疫苗的科學(xué)家表示，在公共領(lǐng)域有更多關(guān)于這種疫苗的信息，據(jù)認(rèn)為它比輝瑞疫苗的研制難度稍微低一點(diǎn)。

Zain Rizvi, research director at the advocacy group Public Citizen, welcomed the news, saying WHO's efforts will address the huge global demand for mRNA vaccines, which have proven to be arguably the most effective at curbing COVID-19.

維權(quán)團(tuán)體“公共公民”的研究主任扎因·里茲維對這一消息表示歡迎，他表示世衛(wèi)組織的努力將解決全球?qū)RNA疫苗的巨大需求，這種疫苗已被證明是遏制新冠病毒最有效的方法。

Rizvi said: “WHO is charting an alternative course that is more open and transparent. But it still needs help.”

里茲維說：“世衛(wèi)組織正在規(guī)劃一條更加開放和透明的替代路線。但它仍然需要幫助?！?/p>

英文來源：美聯(lián)社

翻譯&編輯：丹妮